Related Experiment Video
Updated: Aug 9, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription
Chie-Hong Wang1, Hui-Chiu Chang, Wen-Chun Hung
1Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.
Abstract:
Previous studies demonstrate that p16, a cyclin-dependent kinase inhibitor and a tumor suppressor, may inhibit matrix metalloproteinase-2 (MMP-2) expression in human cancer cells to suppress tumor invasion and metastasis. However, the detailed mechanism is still unclear. Our results show that p16 inhibits MMP-2 expression via transcriptional repression. Promoter deletion and mutation analysis indicates that p16 acts through the Sp1 transcription factor-binding site located between -72 and -64 bp region from the transcriptional start site of the human MMP-2 promoter to repress gene expression. DNA affinity precipitation assay (DAPA) and chromatin immuno-precipitation (CHIP) assay demonstrate that Sp1 proteins constitutively bind to this consensus sequence in vitro and in vivo. p16 attenuates Sp1 binding to the MMP-2 promoter to suppress gene transcription and overexpression of Sp1 may counteract p16-induced downregulation of MMP-2. CyclinA/CDK complex may directly phosphorylate Sp1 and enhance its DNA-binding activity. Thus, we investigated the effect of p16 on the interaction between cyclin A and Sp1. Our results indicate that p16 induces downregulation of cyclin A and CDK2, reduces the interaction between cyclin A and Sp1, and attenuates phosphorylation of Sp1. Ectoexpression of cyclin A counteracts p16-mediated inhibition of DNA binding of Sp1 and activates MMP-2 promoter activity and mRNA expression. Collectively, our results suggest that p16 suppresses MMP-2 by blocking Sp1-mediated gene transcription.
Insights
The tumor suppressor p16 inhibits matrix metalloproteinase-2 (MMP-2) by blocking Sp1 transcription factor binding to the MMP-2 promoter, thus reducing cancer cell invasion and metastasis.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Background:
- p16, a cyclin-dependent kinase inhibitor and tumor suppressor, is implicated in inhibiting matrix metalloproteinase-2 (MMP-2) expression.
- The precise molecular mechanisms by which p16 suppresses MMP-2 in human cancer cells remain incompletely understood.
Purpose of the Study:
- To elucidate the detailed mechanism by which p16 inhibits MMP-2 expression.
- To investigate the role of Sp1 transcription factor and its interaction with p16 in regulating MMP-2 transcription.
Main Methods:
- Promoter deletion and mutation analysis of the human MMP-2 promoter.
- DNA affinity precipitation assay (DAPA) and chromatin immunoprecipitation (CHIP) assays.
- Investigation of the interaction between p16, Sp1, cyclin A, and CDK2.
Main Results:
- p16 represses MMP-2 gene expression transcriptionally by targeting an Sp1 binding site (-72 to -64 bp) on the MMP-2 promoter.
- p16 attenuates Sp1 binding to the MMP-2 promoter, an effect counteracted by Sp1 overexpression.
- p16 downregulates cyclin A and CDK2, reducing Sp1 phosphorylation and DNA-binding activity.
Conclusions:
- p16 suppresses MMP-2 expression and subsequent tumor invasion/metastasis by inhibiting Sp1-mediated gene transcription.
- The p16-mediated suppression of MMP-2 involves the downregulation of cyclin A/CDK2, leading to reduced Sp1 activity.
Related Concept Videos
Abnormal Proliferation
The JAK-STAT Signaling Pathway
Role of Matrix Metalloproteases in Degradation of ECM
A...
Epigenetic Regulation
X-chromosome...
MicroRNAs
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...